anxiety symptoms and depressive symptoms

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)